Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corp (NQ: GERN )

3.620 +0.020 (+0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Geron Corp

< Previous 1 2 3 Next >
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
From Geron Corporation
Via Business Wire
Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Present at Upcoming Investor Conferences in April
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones
From Geron Corporation
Via Business Wire
Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference
From Geron Corporation
Via Business Wire
Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.
From Geron Corporation
Via Business Wire
Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million
From Geron Corporation
Via Business Wire
Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Geron Corporation
Via Business Wire
Geron Corporation Announces Proposed Public Offering of Common Stock
From Geron Corporation
Via Business Wire
Geron (NASDAQ: GERN) Reports Positive Results From IMerge Phase 3 Trial of Imetelstat for Lower Risk MDS
Geron Corporation (NASDAQ: GERN) is engaged as a late-stage biopharmaceutical company, which is focused on the research and development of 
Via Spotlight Growth
Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces Conference Call for Top-Line Results from IMerge Phase 3
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate in Stifel 2022 Healthcare Conference
From Geron Corporation
Via Business Wire
Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022
From Geron Corporation
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.